- ISIN
- US0554771032
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 13, 2024
Highlights
- Market Cap
- $1.49B
- Enterprise Value
- $1.17B
- EPS (TTM)
- -$2.80
- EBITDA (TTM)
- -$169.60M
- Year Range
- $8.48 - $24.60
- Target Price
- $28.60
- ROA (TTM)
- -28.42%
- ROE (TTM)
- -30.61%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
BCAX Performance Chart
Bicara Therapeutics Inc (BCAX) is up 45.9% since the beginning of the year. At $25 per share, BCAX is currently trading at its 52-week high.
Loading charts...
Returns By Period
Bicara Therapeutics Inc (BCAX) has returned 45.87% so far this year and 163.41% over the past 12 months.
Bicara Therapeutics Inc
- 1D
- 5.68%
- 1M
- 13.24%
- YTD
- 45.87%
- 6M
- 34.01%
- 1Y
- 163.41%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
BCAX Monthly Returns History
Based on dividend-adjusted daily data since Sep 13, 2024, BCAX's average daily return is +0.11%, while the average monthly return is +0.91%. At this rate, an investment would double in approximately 6.4 years.
Historically, 55% of months were positive and 45% were negative. The best month was Sep 2025 with a return of +32.2%, while the worst month was May 2025 at -35.6%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.
On a daily basis, BCAX closed higher 50% of trading days. The best single day was Sep 29, 2025 with a return of +18.5%, while the worst single day was May 23, 2025 at -40.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.18% | -0.12% | 18.53% | 8.50% | 0.79% | 12.87% | 45.87% | ||||||
| 2025 | -27.55% | 5.39% | -2.03% | 10.28% | -35.63% | 0.43% | 19.59% | 7.47% | 32.24% | 2.91% | 14.22% | -9.32% | -3.39% |
| 2024 | -2.97% | -7.03% | -12.20% | -16.21% | -33.64% |
Benchmark Metrics
Bicara Therapeutics Inc has an annualized alpha of 2.26%, beta of 1.42, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since September 13, 2024.
- This stock tended to rise when S&P 500 Index fell (downside capture of -44.70%), but participation in market rallies was also limited (-21.54%) - a profile typical of counter-cyclical assets.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 2.26%
- Beta
- 1.42
- R²
- 0.09
- Upside Capture
- -21.54%
- Downside Capture
- -44.70%
Return for Risk
Risk / Return Rank
BCAX ranks 92 for risk / return — in the top 92% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Bicara Therapeutics Inc (BCAX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BCAX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.67 | ||
| Sortino ratioReturn per unit of downside risk | +0.40 | ||
| Omega ratioGain probability vs. loss probability | 1.37 | 1.37 | 0.00 |
| Calmar ratioReturn relative to maximum drawdown | 6.22 | 2.78 | +3.44 |
| Martin ratioReturn relative to average drawdown | 15.58 | 12.44 | +3.15 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Bicara Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Bicara Therapeutics Inc was 67.82%, occurring on Jun 27, 2025. The portfolio has not yet recovered.
The current Bicara Therapeutics Inc drawdown is 9.31%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -67.82%Jun 2025 | 9mo 12d | — | 1y 9moSep 2024 - now |
2024 correction2024 | -10.82%Sep 2024 | 0s | 4d | 4dSep 2024 - Sep 2024 |
Drawdown Indicators
| BCAX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.82% | -56.78% | -11.04% |
Max Drawdown (1Y)Largest decline over 1 year | -26.43% | -9.10% | -17.33% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -9.31% | -1.80% | -7.51% |
Average DrawdownAverage peak-to-trough decline | -39.50% | -10.71% | -28.79% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.53% | 2.03% | +8.50% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Bicara Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Bicara Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for BCAX in comparison with other companies in the Biotechnology industry. Currently, BCAX has a P/B value of 2.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with BCAX
Add Bicara Therapeutics Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with BCAX